The US Food and Drug Administration (FDA) has granted approval for Sagent Pharmaceuticals’ bupivacaine hydrochloride injection.

The drug is indicated for the production of local or regional anaesthesia or analgaesia for dental and oral surgery procedures, diagnostic and therapeutic procedures, and obstetrical procedures.

Developed by Strides Arcolab, the injection will be available in six single-dose and two multi-dose latex-free vials.

Strides is responsible for developing and supplying injectable products that Sagent will market in the US.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData